However, Miller et al. described a 14.8% incidence of occult
CNS involvement in heavily pretreated breast cancer patients
identified as part of eligibility screening for four clinical trials,
with a median time of 12 months from first distant metastasis
to CNS screening study identifying CNS metastases (11).